Because symptoms are similar to those of gastroesophageal reflux disease, achalasia is often misdiagnosed, explained Eric Low, MD, MPH, gastroenterology fellow at University of California, San Diego at Digestive Disease Week 2022.
Eric Low, MD, MPH, gastroenterology fellow at University of California, San Diego, explained the clinical manifestation of ahcalsia and the challenges of diagnosing the rare condition at Digestive Disease Week 2022.
Transcript
Can you explain what achalasia is, and how it manifests clinically?
Achalasia, it's a rare esophageal motility disorder. It's characterized by impaired relaxation of the lower esophageal sphincter, so it's the sphincter that connects the esophagus to the stomach. Normally, during swallowing, when you initiate a swallow, the lower esophageal sphincter will open up and allow food to go from the esophagus into the stomach. A normal transition.
Another characteristic feature of achalasia is ineffective esophageal peristalsis. Patients with achalasia don't have the ability to normally move food down the esophagus like in normal physiology. Individuals with a achalasia unfortunately have a double whammy against normal swallowing. They can't move the food in the right direction, and then they also have to push against a tight sphincter down to the bottom of the esophagus that is hard to push against. As you can imagine, individuals and achalasia have typically dysphasia for both solids and liquids. Other common symptoms of achalasia include regurgitation, heartburn, noncardiac chest pain, and weight loss.
As a rare disorder, is there a delay in diagnosis for achalasia? What are the challenges around misdiagnosis?
Achalasia is a rare disease in general. The incidence is about 1 in 100,000 persons per year, and then the prevalence is about 10 per 100,000 persons per year. It is often misdiagnosed because there's so much overlap in symptoms with gastroesophageal reflux disease (GERD), which is very, very prevalent and has a very high incidence in the US.
There's a recent study that showed about greater than 80 million people will experience symptoms of GERD, so sometimes achalasia patients are misdiagnosed as having gastroesophageal reflux disease or GERD because of the overlap in symptoms such as heartburn, regurgitation. In order to bridge this gap and reduce the amount of time that patients spend with the symptoms or amount of time being undiagnosed with achalasia, typically patients will undergo an upper endoscopy procedure. That can often be normal, so the esophagus can look normal, and patients, again, are still misdiagnosed as having gastroesophageal reflux disease. So it is important, if they still continue to have symptoms despite being on PPI [proton-pump inhibitor] therapy, that they undergo additional evaluation with either a barium esophagram or high resolution esophageal manometry in order to diagnose their dysphasia issue.
ATS 2024: Bridging the Past, Present, and Future of Respiratory Care
May 16th 2024The application of artificial intelligence in medicine is anticipated as a highlight of ATS 2024, with sessions exploring its applications in research, radiological interpretation, and pediatric pulmonology.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Tackling Health Inequality: The Power of Education and Experience
April 30th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.
Listen
Posters Characterize DMD Caregiver Experiences, Impact of Gene Therapy on Caregiving Demands
May 10th 2024Posters presented at the ISPOR—The Professional Society for Health Economics and Outcomes Research meeting explored Duchenne muscular dystrophy (DMD) caregiver experiences and gene therapy’s impact on work opportunities for caregivers.
Read More